Status:
RECRUITING
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort....
Eligibility Criteria
Inclusion
- Enrollment in the UAB-ADC study under a separate IRB-approved research protocol.
- Enrollment in the UAB-ADC amyloid-PET substudy under a separate IRB-approved research protocol. The amyloid-PET study does not have to have been completed prior to enrollment and participation in this tau-PET study.
- Negative urine or serum hCG test within 2 days of \[F-18\]AV-1451 administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
Exclusion
- Meets any exclusion criteria for the UAB-ADC study.
- Inability or contraindication for undergoing MRI and/or PET imaging
- Inability to participate in the imaging studies due to severity of dementia
Key Trial Info
Start Date :
July 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT03809351
Start Date
July 8 2020
End Date
July 1 2028
Last Update
December 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB
Birmingham, Alabama, United States, 35233